FDA widens Vertex’s Casgevy use for paediatric patients

The U.S. Food and Drug Administration has expanded the approved use of Vertex Pharmaceuticals’ Casgevy to include pediatric patients. This regulatory update allows for the treatment of younger populations with the therapy, broadening its clinical application. The expansion represents a key development for Vertex as it seeks to increase the reach of its pharmaceutical offerings in the pediatric market.